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AbstrAct
Background Immune checkpoint inhibitors are 
successfully introduced as anticancer treatment. However, 
they may induce severe immune-related adverse events 
(irAEs). One of the most frequent irAEs is diarrhoea. The 
main objective of this study was to analyse symptoms  
(ie, grade of diarrhoea), endoscopic and histological 
features and response to management in immune 
checkpoint inhibition-related colitis (IRC).
Patients and methods We retrospectively analysed 
patients who developed diarrhoea on checkpoint inhibition 
and therefore underwent an endoscopy and/or were 
treated with corticosteroids. Patients were treated between 
August 2010 and March 2016 for metastatic melanoma 
or non-small cell lung cancer. Severity of IRC was scored 
using the endoscopic Mayo score and the van der Heide 
score.
Results Out of a cohort of 781 patients, 92 patients 
were identified who developed diarrhoea and therefore 
underwent an endoscopy and/or were treated with 
corticosteroids. Patients were treated with monotherapy 
anticytotoxic T-lymphocyte antigen-4, antiprogrammed 
death receptor-1 or a combination of both. All patients had 
symptoms of diarrhoea (grade 1: 16%; grade 2: 39% and 
grade 3: 44%). A complete colonoscopy was performed 
in 62 (67%) patients, of whom 42 (68%) had a pancolitis 
(≥3 affected segments). Ulcers were seen in 32% of 
endoscopies. There was no significant correlation between 
the grade of diarrhoea at presentation and endoscopic 
severity scores, the presence of ulcers or histological 
features. In 54 episodes of diarrhoea (56%), patients 
received one or more cycles infliximab for  
steroid-refractory colitis. Patients with higher endoscopic 
severity scores, ulcers and/or a pancolitis needed 
infliximab more often.
Conclusions The correlation between grade of diarrhoea 
and endoscopic or histological features for severity of 
colitis is poor. Patients with higher endoscopic severity 
scores, ulcers or a pancolitis needed the addition of 
infliximab more often. Therefore, endoscopy may have 
value in the evaluation of the severity of IRC and may help 
in decision making for optimal management.
IntRoduCtIon
The introduction of immune checkpoint 
inhibitors has changed treatment options and 
improved survival of patients with advanced 
cancer. Ipilimumab, a monoclonal antibody 
blocking cytotoxic T-lymphocyte antigen-4 
(CTLA-4) on T cells, showed an overall 
survival benefit in patients with advanced 
melanoma.1 Nivolumab and pembrolizumab, 
both antibodies blocking programmed death 
Key questions
What is already known about this subject?
 ► Immunotherapy can induce adverse events, which 
are predominantly immune related.
 ► One of the most common and severe immune-
related adverse events is diarrhoea.
 ► Diarrhoea is seen in 35% of patients treated 
with anticytotoxic T-lymphocyte antigen-4, 20% 
in patients treated with antiprogrammed death 
receptor-1 and even 44% in patients treated with 
the combination therapy.
What does this study add?
 ► Patients in which ulcers were seen during 
endoscopy required significantly more often the 
addition of infliximab for steroid-refractory colitis 
compared with patients in which no ulcers were 
seen.
 ► Patients with a high van der Heide score, a high 
Mayo score or a pancolitis required significantly 
more often the addition of infliximab for steroid-
refractory colitis compared with patients with a 
low van der Heide score, low Mayo score or no 
pancolitis.
 ► There was no significant correlation between the 
grade of diarrhoea at presentation and endoscopic 
Mayo score, van der Heide score or presence of 
ulcers.
 ► There was no correlation between the presence of 
abdominal pain and any endoscopic feature.
 ► The most common histopathological feature was 
an increase in lamina propria cellularity, primarily 
consisting of mononuclear cells. The second most 
common histopathological feature was neutrophilic 
infiltration, either intraepithelial or as crypt 
abscesses.
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receptor-1 (PD-1), improved survival compared with 
chemotherapy and ipilimumab.2 3 The combination of 
ipilimumab with an anti-PD-1 antibody improves overall 
response rate and progression free survival even further 
compared with single agent therapy.4 Checkpoint inhib-
itors also show activity in several other types of cancer, 
such as metastatic non-small cell lung cancer (NSCLC) 
and bladder cancer.5–7 Although efficacy and durability 
of response with checkpoint inhibitors has been well 
established, one of the major concerns is the high rate of 
adverse events that are predominantly immune related. 
diarrhoea
One of the most common and severe immune-related 
adverse events is diarrhoea, with an incidence of 35% 
for anti-CTLA-4, 20% for anti-PD-1 and even 44% for the 
combination therapy.4 8 The median time to onset of diar-
rhoea is 7–8 weeks after start for ipilimumab (or combi-
nations with ipilimumab), compared with 3–6 months 
for anti-PD-1.9–12 The Common Terminology Criteria for 
Adverse Events (CTCAE version 4.03) are often used to 
define grades of diarrhoea in patients treated in clinical 
trials. Grade 1 diarrhoea is defined as an increase of <4 
stools over baseline, grade 2 as between 4 and 6 stools 
over baseline, grade 3 as ≥7, grade 4 as life-threatening 
consequences and grade 5 as death.
treatment algorithms
Current treatment algorithms for immune checkpoint 
inhibition-related colitis (IRC) are based on symptoms of 
diarrhoea graded according to CTCAE.10–13 For patients 
with grade 2 diarrhoea, delay of immunotherapy and start 
of symptomatic treatment with loperamide are consid-
ered. If symptoms persist for >3 days, oral corticoster-
oids in a dose of 0.5–1.0 mg/kg are recommended. For 
patients with grade 3 or 4 diarrhoea, discontinuation of 
immunotherapy (IT) and treatment with 1.0–2.0 mg/kg 
prednisone is advised. Steroid-refractory colitis is defined 
as the persistence of symptoms within 3 days of high-dose 
corticosteroids. These patients could be treated with the 
addition of 5 mg/kg infliximab. The implementation of 
these treatment algorithms has resulted in a decrease 
of serious complications such as perforation and colec-
tomy.14 According to these algorithms, a lower endos-
copy is advised for patients with grade 3 or 4 symptoms 
of diarrhoea, but no recommendations are provided on 
differential treatment based on endoscopic findings. The 
aim of this study was to try to correlate symptoms, endo-
scopic features, histology and response to management 
in patients who developed diarrhoea on immune check-
point inhibition.
Methods
Patients
Patients who developed diarrhoea on immunotherapy and 
therefore underwent an endoscopy and/or were treated 
with corticosteroids were retrospectively identified. All 
patients were treated for melanoma or NSCLC, between 
August 2010 and March 2016. Patients were treated with 
monotherapy anti-CTLA-4, anti-PD-1, a combination of 
both or the combination of anti-CTLA-4 and radiofre-
quency ablation (RFA). Diarrhoea was scored according 
to CTCAE version 4.03. All patient characteristics were 
derived from the electronic patient records. Routinely, 
stools were tested for microorganisms, including SSYC, 
Clostridium difficile and viral pathogens. Severity of IRC on 
endoscopy was scored retrospectively using two different 
scoring systems (online supplementary table 1). Endo-
scopic characteristics of IRC are very diverse, and there 
are no available validated scoring systems. Often, a diffuse 
component of inflammation was present, and therefore 
we used the Mayo score, which is validated for scoring 
diffuse inflammation seen in ulcerative colitis (UC).15 
However, this score is not ideal in patients with ulcers 
among a normal or slightly friable mucosa. When ulcers 
were present in a further normal mucosa, a Mayo score 
of 0 with a positive ulcer score was given in our study. We 
also used the van der Heide score, as it is more descriptive 
and therefore potentially more useful for the diverse char-
acteristics seen in IRC. This score has been used previ-
ously for this purpose.16 17 However, the van der Heide 
score does not take into account the extensiveness of 
inflammation. Therefore, numbers of affected segments 
of the colon (rectosigmoid, descending, transverse and 
ascending) were scored separately. Involvement of ≥3 
segments was defined as pancolitis. Scores were gathered 
through saved images and endoscopy reports and revised 
by one gastroenterologist (JvD), blinded for the grade 
of diarrhoea. As the scores may be influenced by subjec-
tivity, the most objective endoscopic feature, namely the 
presence of ulcers, was analysed as a separate variable. An 
ulcer was defined as a mucosal break of ≥0.5 cm. All H&E 
stained slides of biopsies taken during endoscopies were 
reassessed by one gastrointestinal pathologist (PS).
treatments
Patients treated with ipilimumab, nivolumab or pembroli-
zumab as monotherapy received standard or flat doses. 
Patients who received the combination of ipilimumab 
and RFA underwent RFA of one liver metastasis, directly 
followed by four cycles of ipilimumab (depending on 
the cohort, either 3 mg/kg or 10 mg/kg every 3 weeks). 
Patients received either the standard combination of 
ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) or a 
Key questions
how might this impact on clinical practice?
 ► Algorithms to guide management of immune-related diarrhoea 
should not be based on the grade of diarrhoea.
 ► Endoscopic features, such as the presence of ulcers or a pancolitis, 
can help clinicians to intensify immune suppression more rapidly.
 ► Histopathology does not seem to have an added value to guide 
therapy beyond what is found endoscopically. Mucosal biopsies 
appear to mainly serve to confirm diagnosis.
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sequential but overlapping scheme of two cycles ipili-
mumab 3 mg/kg on days 1 and 22 followed directly by 
nivolumab (3 mg/kg) or pembrolizumab (2 mg/kg) 
from day 23 and onwards every 2 weeks or every 3 weeks, 
respectively.
statistical analysis
For continuous variables, data are presented as median 
with IQR and categorical variables as a number (%). 
Correlations between clinical symptoms and the endo-
scopic features were assessed using Spearman rank corre-
lation coefficient. Associations between clinical symp-
toms, endoscopic features, histology and outcome of 
management were analysed by χ2 tests. A P value of <0.05 
was considered statistically significant. Statistical analysis 
was performed using SPSS V.22.
Results
Patient characteristics
Out of a cohort of 781 patients, 92 patients were identified 
who developed diarrhoea and therefore underwent an 
endoscopy and/or were treated with corticosteroids. All 
patient characteristics have been summarised in table 1. 
Four patients had two different episodes of diarrhoea 
(median days between episodes 318 days; range 190–632). 
Mean age was 58 years (range 30–88) and 54% of patients 
were female. Eighty patients were treated for metastatic 
melanoma (87%), and 12 patients (13%) were treated for 
metastatic NSCLC. Fifty-six per cent (54/96) of episodes 
were due to anti-CTLA-4 (of which 10/54 received the 
combination with RFA), 22% due to anti-PD-1% and 
22% due to the combination of anti-CTLA-4 and anti-
PD-1. In 16% of episodes patients had grade 1 diarrhoea, 
39% had grade 2 diarrhoea and 44% had grade 3 diar-
rhoea. In 48 episodes (50%) patients also experienced 
abdominal pain and in 29 episodes (30%) patients had 
bloody stools. Infectious causes for diarrhoea were ruled 
out in 68 episodes (71%). Three patients had a positive 
stool culture for which they were treated with antibiotics. 
However, as symptoms did not resolve, an IRC component 
was present as well. The median time between the first 
cycle of immunotherapy and onset of diarrhoea was 38 
days (IQR 23–62). For patients treated with ipilimumab, 
the median time to onset of diarrhoea was 33 days, for 
anti-PD-1 84 days and for the combination 27 days. Three 
patients developed a perforation of the colon, for which 
they underwent surgery (online supplementary table 2). 
No patients died due to colitis.
endoscopic results
In all but three episodes an endoscopy was performed. 
Endoscopy images were not available in one episode. 
These four patients were excluded from endoscopic and 
histopathological analysis. The median time between 
start of diarrhoea and endoscopy was 8 days (IQR 5–14), 
the median endoscopic Mayo score was 1 (range 0–3) and 
the median van der Heide score was 6 (range 0–12). 
Ulcers were seen during 29 endoscopies (32%). In the 
majority of endoscopies (79%), a continuous pattern 
of inflammation was seen. A complete colonoscopy was 
performed in 62 (67%) patients, of whom 42 (68%) had a 
pancolitis (≥3 affected segments). No serious side effects 
of colonoscopy were seen in our patients. All endoscopic 
features are summarised in table 2. There was no signifi-
cant correlation between grade of diarrhoea at presenta-
tion and endoscopic Mayo score (ρ 0.12; P=0.28), van 
Table 1 Patient characteristics
No. (%)
Age median (range) 58 (30–88)
Gender
  Male 42 (46)
  Female 50 (54)
Type of cancer
  Melanoma 80 (87)
  NSCLC 12 (13)
Immunotherapy among 96 episodes
  Ipilimumab (3 mg/kg) 44 (46)
  Ipilimumab (10 mg/kg) 10 (10)
  Nivolumab 11 (12)
  Pembrolizumab 10 (10)
  Sequential ipilimumab+pembrolizumab 7 (7)
  Sequential ipilimumab+nivolumab 2 (2)
  Combined ipilimumab+nivolumab 12 (13)
Diarrhoea at presentation among 96 episodes
  Grade 1 15 (16)
  Grade 2 37 (39)
  Grade 3 43 (44)
  Grades 4–5 0 (0)
  Unknown 1 (1)
Prednisone at start of diarrhoea
  None 4 (4)
  <1 mg/kg 32 (33)
  1 mg/kg 57 (60)
  >1 mg/kg 3 (3)
Budesonide
  No 84 (87)
  Yes 12 (13)
Infliximab
  No 42 (44)
  Yes 54 (56)
Mycophenolic acid
  No 93 (97)
  Yes 3 (3)
Tacrolimus
  No 94 (98)
  Yes 2 (2)
NSCLC, non-small cell lung cancer.
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der Heide score (ρ 0.13; P=0.23) or presence of ulcers (ρ 
0.12; P=0.25). Also, no correlation was found between the 
presence of abdominal pain and any endoscopic feature. 
A correlation was found between the presence of bloody 
stools and the endoscopic scores: Mayo: ρ 0.35 (P=0.001) 
and van der Heide: ρ 0.43 (P<0.001). There was no differ-
ence in the presence of ulcers in patients with grade 2 
(37%) or grade 3 diarrhoea (33%; P=0.73). In 15 (24%) 
of the complete colonoscopies, the ascending colon was 
more severely affected than the descending colon (an 
example can be seen in figure 1E,F). Moreover, in 5 out 
of 64 colonoscopies (8%), endoscopic signs of inflamma-
tion were only seen in the ascending colon. Endoscopic 
features and their association with symptoms and treat-
ment management have been summarised in table 3.
histological features
In 90 episodes (94%), biopsies were taken during endos-
copy. Histopathological features have been summa-
rised in table 4. In the majority of episodes, patients had 
received immunosuppressive drugs before the endoscopic 
Table 2 van der Heide and endoscopic Mayo scores from 
92 endoscopies
Endoscopic feature according to the van der 
Heide classification No. (%)
Color
  Normal 12 (13)
  Red 58 (63)
  Deeply red 22 (24)
Vascular patter
  Normal 18 (20)
  Partially absent 45 (49)
  Completely absent 29 (31)
Friability
  Normal 17 (19)
  Slightly friable 48 (52)
  Severely friable 27 (29)
Granularity
  Absent 23 (25)
  Fine granularity 62 (67)
  Coarse granularity 7 (8)
Rectal valves
  Sharp 46 (50)
  Swollen 46 (50)
  Absent 0 (0)
Ulcers
  Absent 63 (69)
  Few 18 (19)
  Multiple 11 (12)
Spontaneous bleeding
  Absent 87 (95)
  Discrete 4 (4)
  Severe 1 (1)
Mucopurulent exudate
  Absent 35 (38)
  Little 35 (38)
  Much 22 (24)
van der Heide score
  Low (0–6) 50 (54)
  High (7–16) 42 (46)
Mayo score*
  0 14 (16)
  1 46 (52)
  2 25 (29)
  3 3 (3)
*The endoscopic Mayo score was available for 88 episodes (four 
episodes could not be classified according to the endoscopic 
Mayo score).
Figure 1 (A–F) Examples of differences in immune 
checkpoint inhibition-related colitis. Figure parts A and B 
show two different patients with grade 2 diarrhoea. Figure 
part A shows no abnormalities on colonoscopy. Figure part 
B shows a swollen, erosive and friable mucosa. Figure parts 
C and B show two different patients with grade 3 diarrhoea. 
Figure part C shows no abnormalities on colonoscopy. 
Figure part D shows a deeply red colon where the vascular 
pattern is partially absent, the mucosa appears severely 
friable and multiple ulcers can be seen. Figure parts E and 
F show a single patient with grade 1 diarrhoea. During 
colonoscopy, the entire descending colon (E) showed no 
abnormalties, while the ascending colon (F) showed a 
swollen, severely friable mucosa, with deep ulcers.
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procedure (52%, n=47). Median days on high-dose ster-
oids was 4 (IQR 2–6). The most common change was 
an increase in lamina propria cellularity (83%, n=75), 
primarily consisting of mononuclear cells (online supple-
mentary figure 1). The second most common change was 
neutrophilic infiltration, either intraepithelial (79%, n=71) 
or as crypt abscesses (62%, n=56). In both circumstances, 
usually mild and patchy. Mild to prominent intraepithelial 
lymphocytosis was present in only 10% (n=9). Small foci 
with minimal increase in intraepithelial lymphocytes were 
noted in an additional 15 cases (17%). Increased numbers 
of apoptotic cells were seen in the crypts in 42% (n=38), but 
usually this was mild (n=28). Outcomes of exploratory asso-
ciation analysis of histopathological features with various 
clinical and endoscopic features are displayed in online 
supplementary table 3. Analogous to endoscopic features, 
none of the histopathological features had an association 
with the grade of diarrhoea. However, multiple histopatho-
logical features were associated with endoscopic features 
(such as Mayo score and the presence of ulcers), bloody 
stools and the need for infliximab. Endoscopic and histo-
pathological features had no association with different types 
of immune check point inhibitors (online supplementary 
table 4). Also, histopathological features did not correlate 
with whether immunosuppressive therapy had been admin-
istered before taking the biopsies (data not shown).
Initial management of IRC
In all but four episodes, patients received high-dose corti-
costeroids. Median time between onset of symptoms and 
start of high-dose corticosteroid therapy was 5 days (IQR 
3–11). Of all 92 episodes of diarrhoea treated with high-
dose corticosteroids, 32 (35%) were initially treated with a 
dosage of <1 mg/kg, 57 episodes (62%) with 1 mg/kg and 
3 episodes (3%) with >1 mg/kg. Patients used high-dose 
corticosteroids for a median of 44 days (IQR 29–73). In 12 
episodes (13%), patients received budesonide as local treat-
ment.
Figure 2 Representative hematoxylin-eosin stained (HE) 
sections demonstrating immune checkpoint inhibition-
related colitis representative HE sections demonstrating 
immune checkpoint inhibition-related colitis characterised 
by increased lamina propria cellularity (A, B and D). 
(A) extension of the infiltrate into the submucosa. (B) 
neutrophilic inflammation with a crypt abscesses, mild 
cryptitis, mucin depletion of epithelial cells and small foci 
with minimal increase in intraepithelial lymphocytes. (C) 
Apoptotic cells in crypt epithelium.  
(D) Prominent intraepithelial lymphocytosis.
Table 3 Endoscopic features and association with symptoms and treatment management in 92 episodes of diarrhoea
Endoscopic features 
Total
No. (%)
Grade of diarrhoea* 
G2/G3 No. (%) P value
Bloody stools 
no/yes No. (%) P value
Need for 
infliximab no/
yes No. (%) P value
Endoscopic Mayo†
  0–1 (low) 60 (68) 21 (44)/27 (56) 0.84 47 (78)/13 (22) <0.01 32 (53)/28 (47) <0.01
  2–3 (high) 28 (32) 12 (46)/14 (54) 13 (46)/15 (54) 6 (21)/22 (79)
Total van der Heide score
  0–6 (low) 50 (54) 20 (49)/21 (51) 0.53 44 (88)/6 (12) <0.01 29 (58)/21 (42) <0.01
  7–12 (high) 42 (46) 15 (42)/21 (58) 19 (45)/23 (55) 12 (29)/30 (71)
Ulcers
  No 63 (69) 22 (44)/28 (56) 0.73 47 (75)/16 (25) 0.06 35 (56)/28 (44) <0.01
  Yes 29 (31) 13 (48)/14 (52) 16 (55)/13 (45) 6 (21)/23 (79)
Pancolitis‡
  No 20 (32) 7 (50)/7 (50) 0.36 17 (85)/3 (15) 0.13 15 (75)/5 (25) <0.01
  Yes 42 (68) 14 (36)/25 (64) 28 (67)/14 (33) 10 (24)/32 (76)
Cases with missing values not included in χ2 test.
*Grade of diarrhoea only G2 versus G3.
†The endoscopic Mayo score was available for 88 episodes (four episodes could not be classified according to the endoscopic Mayo score).
‡Pancolitis only available for 62 episodes in which a full colonoscopy was performed.
 o
n
 6 August 2018 by guest. Protected by copyright.
http://esm
oopen.bmj.com/
ESM
O
 O
pen: first published as 10.1136/esm
oopen-2017-000278 on 13 January 2018. Downloaded from
 
Open Access
6 Geukes Foppen MH, et al. ESMO Open 2018;3:e000278. doi:10.1136/esmoopen-2017-000278
steroid-refractory colitis
In 54 (56%) episodes, patients required infliximab (5 mg/
kg) for corticosteroid-refractory colitis, and of those 
patients, 50% (n=27) were given more than one cycle 
infliximab. Median time between start of prednisone and 
start of infliximab was 9 days (IQR 5–19.5), and median 
time to response on infliximab was 2 days (IQR 1–4). In 
three episodes, patients required additional immunosup-
pressive agents such as mycophenolic acid or tacrolimus. 
None of 15 patients with grade 1 diarrhoea required 
infliximab therapy. We did not see any difference in the 
requirement of infliximab for patients that presented 
with grade 2 (68%) or grade 3 (67%) diarrhoea. Inter-
estingly, in 79% of episodes in which ulcers were seen 
during endoscopy, patients needed infliximab, while this 
was only the case for 44% of episodes in which no ulcers 
were seen (P=0.002). Patients with a van der Heide score 
between 7 and 12 (high score) received infliximab in 71% 
of episodes, while this was 42% in case of a van der Heide 
score of 0–6 (low score; P=0.005). Similarly, with these 
data, 79% of patients with a Mayo score of 2–3 (high score) 
received infliximab compared with 47% for patients with 
a Mayo score of 0–1 (low score; P=0.005). Seventy-six per 
cent of patients with a pancolitis (≥3 affected segments) 
required infliximab, while this was only the case in 25% 
of patients with <3 affected segments (P<0.001). In total, 
6 patients (16%) had a response (complete response 
(CR) or partial response (PR)) in the group who did not 
Table 4 Histopathological features of biopsies taken in 90 
endoscopies
Histopathological feature No. (%)
Lamina propria cellularity
  Normal 15 (17)
  Increased
   Focal 7 (8)
   Patchy 24 (27)
   Diffuse, superficial 4 (4)
   Diffuse, transmucosal – mild 24 (26)
   Diffuse, transmucosal – moderate 16 (18)
   Diffuse, transmucosal – severe 0 (0)
Crypt architecture
  Normal 58 (64)
  Irregular – mild 23 (26)
  Irregular – moderate 8 (9)
  Irregular – severe 1 (1)
Mucosal surface
  Flat/normal 74 (82)
  Irregular 15 (17)
  Villous 1 (1)
Apoptotic cells in crypt epithelium
  Absent/hardly any 52 (58)
  Mild 28 (31)
  Moderate 6 (7)
  Severe 4 (4)
Extension of chronic inflammatory infiltrate into submucosa
  Not present 46 (58)
  Present 33 (42)
Location of intraepithelial neutrophilic infiltration
  Absent 19 (21)
  Present in crypt epithelium 8 (9)
  Present in superficial epithelium 16 (18)
  Present in crypt and superficial epithelium 47 (52)
Grade of intraepithelial neutrophilic infiltration
  None 19 (21)
  Minimal 15 (17)
  Mild 46 (51)
  Moderate 10 (11)
  Severe 0 (0)
Neutrophilic crypt abscesses
  Absent 34 (38)
  Mild 46 (51)
  Moderate 8 (9)
  Severe 2 (2)
Location of intraepithelial lymphocytosis
  Absent 66 (73)
Continued
Histopathological feature No. (%)
  Present in crypt epithelium  (5)
  Present in superficial epithelium 8 (9)
  Present in crypt and superficial epithelium 12 (13)
Grade of intraepithelial lymphocytosis
  Absent 66 (73)
  Minimal and patchy 15 (17)
  Mild 6 (7)
  Moderate 2 (2)
  Severe 1 (1)
Mucin depletion of epithelial cells
  Not present 46 (51)
  Mild 32 (36)
  Moderate 10 (11)
  Severe 2 (2)
Ulceration
  Absent 71 (79)
  Present 19 (21)
Granuloma
  Absent 85 (94)
  Present in lamina propria 4 (5)
  Present in submucosa 1 (1)
Table 4 Continued 
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receive infliximab versus 10 patients (22%) in the group 
who did receive infliximab (P=0.53). Also when looking 
at disease control rate (stable disease+PR+CR), there 
was no significant difference in response in patients who 
received infliximab versus those who did not. Disease 
control rate was 59% (22 out of 37 patients) in the group 
of patients who did not receive infliximab versus 44% 
(20 out of 46 patients) in the group of patients who did 
receive infliximab (P=0.15). No serious infliximab-related 
side effects were seen.
Colitis and best overall response
In total 60 patients with colitis and a cutaneous mela-
noma had an evaluable response. In the group of patients 
treated with anti-CTLA-4 monotherapy, the response rate 
was 18% (7 out of 39 patients). In the group of patients 
treated with anti-PD-1 monotherapy, the response rate 
was 44% (four out of nine patients), and it was 33% (4 
out of 12) for patients treated with the combination of 
anti-CLTA-4 and anti-PD-1. These response rates appear 
not different from what has been demonstrated in phase 
III clinical trials (Checkmate-069 and Checkmate-067 or 
Keynote-006).
dIsCussIon
In this retrospective study on IRC, we have shown that 
there is no significant difference between patients with 
grade 2 or 3 diarrhoea with regard to endoscopic severity 
scores, histopathological features, the requirement for 
infliximab or the presence of ulcers. This is important 
because IRC is usually managed based on the grade of diar-
rhoea according to the CTCAE. Instead, we have found a 
correlation between endoscopic features and the need for 
immune suppression beyond high-dose corticosteroids. 
In that light, our findings are relevant, as they would help 
the clinician to more rapidly intensify immune suppres-
sion, with the aim to reduce the time to recovery. Endo-
scopic characteristics in IRC are very diverse, and there 
are no available validated scoring systems. Of note, due 
to the retrospective nature of our study, the endoscopic 
findings may have influenced physicians in their choice 
for management. Based on our findings, we suggest that 
these variables are taken into account in future scores for 
IRC. Our study suggests that the presence of ulcers and 
pancolitis (≥3 affected colon segments) are predictors of 
steroid-refractory colitis, perhaps warranting immediate 
start of infliximab on colonoscopy.
Given the rapid improvement in symptoms after inflix-
imab treatment (median time to response on infliximab 
was 2 days), we therefore strongly advise to consider the 
use of infliximab earlier, especially in patients with ulcer-
ations or pancolitis. Furthermore, our study supports the 
findings by Schadendorf et al,18 who showed that inflix-
imab did not seem to affect the development of a response 
or the durability of response. The rationale of early initi-
ation of infliximab is based on its efficacy in patients with 
IBD. In IBD, treatment with infliximab resulted in more 
clinical responses, mucosal healing, sparing of steroids, 
fewer admissions to the hospital and less surgical inter-
ventions.19 20 An earlier start of infliximab—top-down 
approach—is now increasingly used in severe cases of 
IBD. Currently, a trial is being performed that investigates 
early treatment with infliximab in immune-checkpoint 
inhibition induced colitis (NCT02763761).
In our study, we have also shown that in 23% of colonos-
copies, the ascending colon was more severely affected 
than the descending colon. In these cases, the severity 
of IRC would have been underestimated by sigmoidos-
copy only. Therefore, performing a full colonoscopy in 
patients that present with grade ≥2 diarrhoea may have 
added value to sigmoidoscopy, as the underestimated 
amount and severity of colonic inflammation may results 
in under treatment of patients. The choice for colo-
noscopy, however, has to be judged in relation to other 
factors such as: burden for the patient and the possibility 
of perforation, which is about 2–4 times higher than that 
of sigmoidoscopy.21 Therefore, if severe ulceration is 
present in the left-sided colon, assessment of the right-
sided colon is not necessary for decisions on further 
management. CT colonography could be used as an 
alternative to colonoscopy, as it has a slightly lower iatro-
genic perforation rate. However, CT colonography has 
low sensitivity for correct detection of acute colitis (64%), 
offers no possibility to take biopsies and still is a consider-
able burden for patients.21–23
In this largest series to date analysing histopathology of 
IRC, we found that IRC is most typically described as an 
increase in lamina propria cellularity (83%), commonly 
extending slightly into the submucosa (42%), combined 
with patchy neutrophilic infiltrate (intraepithelial: 79% 
and/or crypt abscesses: 62%). In 36% of cases, there were 
also some irregularities in the crypt architecture present 
but still the overall morphology appeared different from 
IBD. This is in line with the results of earlier analyses.17 24 
Some cases showed an increase in intraepithelial lympho-
cytes and/or apoptosis, but these features were inconsis-
tent. Histopathological features neither correlate with 
the different types of immune checkpoint inhibitors used 
nor with the time point of start of immunosuppression 
(before or after biopsies were taken). Many of the histo-
pathological features were correlated with endoscopic 
features. Therefore, histopathology did not seem to have 
an added value to guide therapy beyond what was found 
endoscopically. Mucosal biopsies appear to mainly serve 
to confirm diagnosis.
Despite the information that is provided by colo-
noscopy and mucosal biopsies, which may help guide 
optimal management of diarrhoea and colitis, one could 
argue that performing a colonoscopy will not change the 
management of IRC. Based on management algorithms, 
patients will start with high-dose steroids and in case of 
insufficient improvement of symptoms, the addition of 
infliximab within several days—all without any guidance 
of information from colonoscopy or mucosal biopsies. 
In addition, colonoscopies are cumbersome for patients, 
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not without risk of perforation and the time benefit 
until infliximab treatment might be marginal with a 
waiting time of several days before a colonoscopy can be 
performed. Currently, it is not known whether omission 
of a colonoscopy affects the outcome of patients devel-
oping immunotherapy-induced gastrointestinal toxicity 
negatively, and therefore should be the subject of further 
studies. Nevertheless, patients with severe IRC should be 
treated promptly to prevent serious complications, such 
as perforation. However, patients with only mild or no 
active colitis, based on endoscopic findings, could be 
sufficiently treated with local steroids only.
Limitations of our study are the retrospective anal-
ysis, the fact that there might be classification bias due 
to the retrospective scoring of symptoms and endoscopic 
severity. Also, biopsies were taken in a non-standardised 
manner.
ConClusIons
The correlation between grade of diarrhoea and endo-
scopic features for severity of colitis is poor. Patients with 
higher endoscopic severity scores, ulcers or a pancolitis 
needed the addition of infliximab more often. There-
fore, endoscopy may have value in the evaluation of the 
severity of IRC and may help in decision making for 
optimal management.
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